Related references
Note: Only part of the references are listed.Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists
Lila Bouadma et al.
INTENSIVE CARE MEDICINE (2020)
Clinical Characteristics of Coronavirus Disease 2019 in China
W. Guan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
Sara Monti et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Covid-19: risk factors for severe disease and death
Rachel E. Jordan et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations
Christien Rondaan et al.
RMD OPEN (2019)
Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders
Jean Jacques Tudesq et al.
AUTOIMMUNITY REVIEWS (2018)
The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
Helena Marco et al.
BMC MUSCULOSKELETAL DISORDERS (2014)
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
Hans-Peter Tony et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Share Paper
